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Abstract
Background: Treatment failure for breast cancer is frequently due to lymph node metastasis and invasion to
neighboring organs. The aim of the present study was to investigate invasion- and metastasis-related genes in
breast cancer cells in vitro and in vivo. Identification of new targets will facilitate the developmental pace of new
techniques in screening and early diagnosis. Improved abilities to predict progression and metastasis, therapeutic
response and toxicity will help to increase survival of breast cancer patients.
Methods: Differential protein expression in two breast cancer cell lines, one with high and the other with low
metastatic potential, was analyzed using two-dimensional liquid phase chromatographic fractionation (Proteome
Lab PF 2D system) followed by matrix-assisted laser desorption/time-of-flight mass spectrometry (MALDI-TOF/MS).
Results: Up regulation of a-subunit of ATP synthase was identified in high metastatic cells compared with low
metastatic cells. Immunohistochemical analysis of 168 human breast cancer specimens on tissue microarrays revealed a
high frequency of ATP synthase a-subunit expression in breast cancer (94.6%) compared to normal (21.2%) and atypical
hyperplasia (23%) breast tissues. Levels of ATP synthase expression levels strongly correlated with large tumor size, poor
tumor differentiation and advanced tumor stages (P < 0.05). ATP synthase a-subunit over-expression was detected on
the surface of a highly invasive breast cancer cell line. An antibody against the ATP synthase a-subunit inhibited
proliferation, migration and invasion in these breast cancer cells but not that of a non-tumor derived breast cell line.
Conclusions: Over-expression of ATP synthase a-subunit may be involved in the progression and metastasis of
breast cancer, perhaps representing a potential biomarker for diagnosis, prognosis and a therapeutic target for
breast cancer. This finding of this study will help us to better understand the molecular mechanism of tumor
metastasis and to improve the screening, diagnosis, as well as prognosis and/or prediction of responses to therapy
for breast cancer.
Keywords: Two-dimensional liquid phase chromatographic fractionation, ATP synthase α-subunit, Tissue microarray,
breast cancer, monoclonal antibody
Background
Breast cancer is one of the most frequently diagnosed
and deadly cancers, with an estimated incidence of 7.6-
9.1/10 000 inhabitants worldwide per year [1]. For some
decades, studies of molecular alterations in tumors have
successfully elucidated some mechanisms of mammary
carcinogenesis, progression and metastasis, and identi-
fied key genes such as ERBB2, TP53, CCND1, BRCA1
and BRCA2 [2,3]. Although the survival of patients has
increased over the last decades due to screening pro-
grams and considerable progress in post-operative adju-
vant systemic therapies (hormone therapy and
chemotherapy) targeting hormonal receptors and the
ERBB2/HER2 receptor [1,4,5], many patient deaths still
occur after metastatic relapse. Prognostic markers cur-
rently accepted for clinical use, such as nodal status,
tumor size, histological grade, steroid receptor status
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and others do not adequately identify patients at an
early stage, increasing the risk of progression and metas-
tasis [6]. Therefore, additional prognostic biomarkers for
the clinical management of breast cancer patients are
needed.
High-throughput genomic and proteomic techniques
provide unprecedented opportunities to tackle the com-
plexity of breast cancer [3,7,8]. A combination of bio-
markers will likely be more sensitive and specific than a
single biomarker to reflect the true heterogeneity of dis-
ease, more reliable for screening, diagnosis, prognosis
and prediction of therapeutic responses, and more use-
ful for finding new therapeutic targets [9]. Among the
currently available techniques, proteomic analysis by
two-dimensional mass spectrometry (2DE-MS) permits
the screening of thousands of modified or unmodified
proteins simultaneously, becoming increasingly popular
for identifying biomarkers for early detection, classifica-
tion and prognosis of tumors, as well as pinpointing tar-
gets for improved treatment outcomes [8,10]. A
relatively newcomer to analytical proteomics is the com-
mercial instrument PF 2D from Beckman Coulter,
which uses chromatographic focusing to separate intact
proteins in the first dimension by pI (from 8.5 to 4.0)
and, in the second dimension, by reversed phase chro-
matography, which separates proteins based on hydro-
phobicity. Thus, the precise detection of isoforms and/
or proteins with post-translational modifications that
alter the pI and/or hydrophobicity is enhanced.
In the present study, we conducted proteomic analysis
on two breast carcinoma cell lines, MCF-7-H and MCF-
7, with different metastasis potentials, by 2D liquid
phase chromatographic fractionation using the PF 2D
system [11,12], followed by matrix-assisted laser deso-
rption/time-of-flight mass spectrometry (MALDI-TOF/
MS), tissue microarray (TMA), immunological and func-
tional analysis. One of the highly over-expressed pro-
teins was identified as the a-subunit of ATP synthase.
ATP synthase is responsible for ATP production in oxi-
dative phosphorylation and can work in reverse as a
proton pumping ATPase [13,14]. ATP synthase expres-
sion is believed to be localized exclusively to mitochon-
dria where it generates most cellular ATP. However,
ATP synthase components have recently been identified
as cell-surface receptors for apparently unrelated ligands
in the course of studies carried out on angiogenesis
[15-17], lipoprotein metabolism [18], innate immunity
[19], hypertension [20] or regulation of food intake [21]
by immunofluorescence, biochemistry and proteomics
analyses [15]. Its molecular mechanism, function and
significance have not been fully established. We detected
the expression of ATP synthase a-subunit protein by
immunohistochemistry (IHC) in different human tumor
samples, including breast cancer, hepatocellular
carcinoma, colon cancer and prostate cancer. As ATP
synthase a-subunit was highly over-expressed in 94.6%
of breast cancer samples tested, the present study is
focused on the expression, functional implication and
potential involvement of ATP synthase in the progres-
sion and metastasis of breast cancer.
Methods
Cell culture conditions
The breast cancer cell line MCF-7 (a gift from Zhi-Hua
Yang, Chinese Academy of Medical Sciences, Peking
Union Medical College, Beijing, China) was cultured in
RPMI 1640 supplemented with 10% fetal bovine serum
(FBS). The highly invasive breast cancer cell line MDA-
MB-231 and the immortalized human breast epithelial
cell line MCF-10F were purchased from American Type
Culture Collection (ATCC, Manassas, VA). MDA-MB-
231 cells were cultured in DMEM medium supplemen-
ted with 10% FBS. MCF-10F cells were cultured in
Ham’s F12 medium supplemented with 10% FBS and 20
μg/ml of epidermal growth factor. All cells were main-
tained at 37°C and 5% CO2.
Selection of a invasive subline from MCF-7 cells
MCF-7 cells were seeded on a Matrigel (Becton Dickin-
son, Franklin Lakes, NJ) coated, 8 μm-pore transwell
(Costar, Cambridge, MA)[12,22,23]. Twenty-four hours
later, cells that had invaded to the other side of the
trans well membrane were collected, expanded and then
re-seeded into another Matrigel coated trans well. Such
selection rounds for highly invasive cells were repeated
six times, resulting in a highly invasive subline desig-
nated as MCF-7-H.
2-D liquid chromatography and MALDI-TOF/MS analysis
The Proteome Lab PF 2D two-dimentional liquid chro-
matography system (Beckman Coulter, CA, USA) con-
sists of 1st dimension chromatofocusing separation
based on pI and 2nd dimension reverse-phase chroma-
tography separation based on hydrophobicity. Chroma-
tofocusing was carried out on the chromatofocusing
column by mixing two buffers with different pH levels,
Starting Buffer (pH 8.5) and Elution Buffer (pH 4.0), to
create a linear pH gradient from 8.5 to 4.0, which was
followed by wash buffer (1 M NaCl). Cell lysates (2 mg)
of MCF-7-H and MCF-7 with different metastasis
potentials were injected onto the chromatofocusing col-
umn equilibrated for 130 min at 0.2 ml/min with the
proprietary starting buffer including urea and a reducing
agent at pH 8.5. Fractions were collected at 0.3-pH
intervals, and each fraction (200-500 μl) was sequentially
analyzed by reverse-phase HPLC. Proteins were sepa-
rated at a flow rate of 0.75 ml/min on a non-porous
C18 reverse phase column using 3.33% B/min linear
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gradient in which solvent A was 0.1% aqueous trifluor-
oacetic acid and solvent B was 0.08% trifluoroacetic acid
in acetronitrile. The different proteins were collected
and digested with trypsin and analyzed by MALDI-
TOF/MS.
Patient selection and TMA
Breast cancer TMAs were purchased from Shanghai
Hujing Biotech Co., Ltd, China and Cybrdi Inc., USA,
which contained duplicates of 194 human breast cancer
tissues and 15 normal breast tissues with a diameter of
1.0 mm. In addition, we collected 13 atypical hyperplasia
of breast tissues and 18 normal breast tissues between
2007 and 2010 from the Cancer Institute (Hospital),
Chinese Academy of Medical Sciences, Peking Union
Medical College, Beijing, China. Ethical approval was
provided by the Chinese Academy of Medical Sciences
Cancer Hospital Ethics Committee. None of the patients
received any neoadjuvant therapy prior to surgery. Prior
patient consent and approval from the Institute
Research Ethics Committee were obtained before we
used these clinical materials for research purposes. Sam-
ples of normal tissues were taken from morphologically
normal areas surrounding diseased tissue. Patients who
received chemotherapy or radiotherapy before surgery
were excluded. Samples with missing and invalid dots
were also excluded. Therefore, in this study 168 female
breast cancer patients (ranging in age from 31 to 82,
with a mean of 58 years), 13 atypical hyperplasia and 33
normal breast tissues were analyzed. All surgically
obtained tissues were fixed in 4% formalin and pro-
cessed routinely. The tumors were classified according
to the Pathological Tumor-Node-Metastasis (pTNM)
system (sixth edition). The pathologic features examined
included histological subtype, tumor size, primary tumor
stage and regional lymph node involvement. The micro-
scopic slides from all specimens were reviewed by at
least two pathologists and one American Society for
Clinical Pathology certified specialist in immunology.
Table II summarizes the clinical pathological parameters
analyzed in this study.
IHC analysis
IHC was performed on 5 μm thick paraffin sections of
tissues and breast cancer TMA. All slides were deparaf-
finized in xylene and rehydrated in graded alcohols. For
antigen retrieval, slides were immersed in 0.01 M citrate
buffer, pH 6.0, and boiled for 10 min in a microwave
oven. Endogenous peroxidase was blocked in 0.3%
H2O2 in PBS for 20 min. To reduce non-specific bind-
ing, sections were pre-incubated in normal goat serum.
The anti-ATP synthase a-subunit mouse monoclonal
antibody (mAb) (7H10-BD4, 1 μg/ml, Invitrogen,
A21350) was incubated on the tissues overnight in a
humidified chamber at 4°C. Subsequently, incubation of
the samples with anti-mouse peroxidase-conjugated
antibody was performed at room temperature for 30
min using a Power Vision Homo-Mouse IHC kit
(ImmunoVision Technologies, Daly City, CA). Hema-
toxylin (Sigma) was used for counterstaining. Positive
controls were included in each staining series. ATP
synthase a-subunit immunopositivity was scored as fol-
lows: 0, no staining or sporadic staining in < 5% of
tumor cells; 1, weak and sporadic staining in 5-25% of
tumor cells; 2, weak staining in 26-50% of tumor cells;
3, strong diffuse cytoplasmic and membrane staining in
26-50% of tumor cells; and 4, strong, diffuse cytoplas-
mic staining and membrane staining in > 50% of tumor
cells. For statistical analysis, negative (0), intermediate
(1+ and 2+) and strongly (3+ and 4+) stained groups
were created. Samples were evaluated under light
microscopy by two independent pathologists and one
American Society for Clinical Pathology certified specia-
list in immunology without prior knowledge of the
patients’ clinical data.
Immunofluorescence analysis of breast cell lines
MDA-MB-231 and MCF-10F cells were grown on glass
cover slips and stained with the anti-ATP synthase a-
subunit antibody as described previously [24]. Briefly,
MDA-MB-231 and MCF-10F cells were washed with
PBS several times before fixation with 4% Para formal-
dehyde. A sample was permeated with 100% ethanol for
5 min at room temperature as a positive control. Cells
were then incubated overnight with the anti-ATP
synthase a-subunit mouse mAb (1 μg/ml) at 4°C and
then washed twice in PBS. Subsequently, immunostain-
ing was carried out for 1 h in the dark with a secondary
antibody against mouse IgG2a conjugated to Alexa
Fluor 488 (1:200, Molecular Probes) in staining buffer.
Samples stained with the isotype mouse IgG2b antibody
served as negative controls. The nuclei were labeled
with PI (Propidium iodide). After final washings, the
cells were mounted and analyzed using a Zeiss LSM-410
(Switzerland) confocal microscope at a magnification of
600×.
Flow cytometry analysis of breast cell lines
MCF-7, MCF-7H, MDA-MB-453, MDA-MB-231 and
MCF-10F cells were incubated at 20°C for 1 h in PBS,
pH 7.4, containing 1% bovine serum albumin (BSA) plus
primary mAbs in order to analyze cell-surface expres-
sion of ATP synthase a-subunit. The cells were then
washed in PBS plus 1% BSA and incubated at 20°C for
30 min with a goat antibody against mouse IgG conju-
gated to Alexa 488 (1:200) and washed three times. A
mouse IgG antibody served as negative controls. Propi-
dium iodide was added to exclude the dead cells before
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analysis on a Coulter XL 4C flow cytometer (Beckman-
Coulter).
Cell proliferation assay
MDA-MB-231 were plated at a density of 5,000 cells/
well in DMEM media depleted of FBS overnight to
allow the cells to become quiescent, and MCF10F cells
were likewise plated in Ham’s F12 medium supplemen-
ted only with 20 μg/ml of epidermal growth factor [25].
Fresh media were added to the wells along with the
anti-ATP synthase a-subunit antibody Mab9E10 (10 μg/
ml, 50 μg/ml, 100 μg/ml). After every 24 h, 10 μl CCK-
8 (Dojindo, Kumamoto, Japan) were added to the cells,
which were then incubated for 2 h at 37°C. The absor-
bance, used to calculate the percent proliferation of the
cells, was measured on a Thermo max plate reader at a
wavelength of 450 nm according to the manufacturer’s
specifications. The MAb9E10 functional mAb generated
against cell surface ATP synthase a-subunit was
reported previously [26]. Briefly, hybridoma cells secret-
ing mAb against ATPase were produced by polyethylene
glycol-mediated fusions and screened by ELISA. Specifi-
city of the mAb was demonstrated by immunofluores-
cence and confocal imaging, as well as flow cytometry
analysis.
Cell migration and invasion assays
Invasion assays were performed in trans well membrane
filter inserts in 24-well tissue culture plates (BD Lab-
ware, Bedford, MA) as described previously [12]. Briefly,
the trans well membrane filter inserts in a 24-well tissue
culture plate contained 6.5 mm diameter, 8- μm pore
size, 10-nm thick polycarbonate membranes. The lower
surface of the porous membrane was coated with 10 μg/
ml human plasma fibronectin at 4°C overnight and then
blocked with 0.1% heat-inactivated BSA (Calbiochem,
San Diego, CA) at 37°C for 45 min. MDA-MB-231 and
MCF-10F cells were detached at 90% confluence with 2
mM EDTA/PBS, washed once in PBS and re-suspended
in serum-free DMEM containing 0.1% BSA. A 300 μl
cell suspension was added to the upper side of the
inserts at a density of 3 × 104 cells/insert before anti-
ATP synthase a-subunit primary mAb (100 μg/ml) and
negative control mIgG (100 μg/ml) were incubated with
the cells for 30 min. DMEM containing 1% FBS was
added to the lower wells. Invasion was allowed to pro-
ceed at 37°C for 8 and 24 h. Cells that did not migrate
through the filters were removed using cotton swabs,
and cells that migrated through the inserts were fixed
and stained with Trypan Blue. The number of migrated
cells per insert was counted under a light microscope at
magnification 20×. Experiments were carried out in tri-
plicate and repeated at least three times. Data from
several independent experiments were pooled and ana-
lyzed using a two-tailed, Student’s t test.
RT2 Profiler PCR array
SABioscience Human Apoptosis PCR Array PAHS-3012
(Qiagen China, Shanghai, China) is an apoptosis path-
way-focused gene expression profiling using real-time
PCR. The system allows one to identify genes involved
in apoptosis and programmed cell death. The array
includes the TNF ligands and their receptors; members
of the bcl-2 family, BIRC (baculoviral IAP repeat)
domain proteins, CARD domain (caspase recruitment
domain) proteins, death domain proteins, TRAF (TNF
receptor-associated factor) domain proteins and cas-
pases. RNA was isolated using RNA easy Mini kit (Qia-
gen). The single strand cDNA from 1 mg total RNA
was synthesized using RT2 First Strand Kit
(SABioscience). Real-time PCR was performed according
to the user manual of RT2 Profiler PCR array system
(SABioscience) using SYBR Green PCR Master Mix in a
Light Cycler 480 system (Roche Diagnostics). Data were
analyzed using Excel-based PCR Array Data Analysis
Templates (SABioscience). Three samples were analyzed:
Control group, MDA-MB-231 cells treated with IgG for
24 hours; Test group 1, MDA-MB-231 cells treated with
MAb9E10 100 mg/ml for 24 hours; Test group 2,
MDA-MB-231 cells treated with MAb9E10 100 mg/ml
for 48 hours.
Statistical analysis
The breast tissue array data were transferred to a PC
and statistically analyzed using SPSS Version 10 for
Windows (SPSS Inc., Chicago, IL). Correlation of the
ATP synthase expression between the several different
clinic pathological factors was calculated with the non-
parametric Spearman correlation coefficient. Results
with a P < 0.05 were deemed statistically significant.
Results
ATP synthase a-subunit is over-expressed in the highly
invasive MCF-7-H subline
To establish an breast carcinoma invasion model, MCF-
7 cells were seeded onto Matrigel-coated trans wells.
The cells were allowed to invade into the lower chamber
of the trans well, collected, expanded and then re-seeded
onto another Matrigel-coated trans well. Cells were har-
vested after four rounds of selection, resulting in the
establishment of a relatively stable, highly invasive sub-
line, MCF-7-H. The invasive ability of this line was
about 3.3-fold greater than that of the MCF-7 parent
cell line (Figure 1A) in Matrigel invasion tests, but equal
to that of the third selection round line, suggesting that
the metastatic potential of the subline reached a plateau
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Figure 1 Identification of ATP synthase a-subunit as a differentially expressed protein between MCF-7-H and MCF-7 cells by PF 2D
and MALDI-TOF-MS. A, The sub-line MCF-7-H was selected from MCF-7 cells for high invasive ability using the trans well invasion assay, cells
were stained with DAPI and the asterisks ** indicate P < 0.01. B, The display map of differentially expressed proteins between the MCF-7-H and
MCF-7 cell lines. The image was analyzed by ProteoVue and DeltaVue software. ProteoVue allows comparison of multiple or all second
dimension runs for one sample in a 2-D map using either gray scale or a color-coded format, where color hue or its intensity is proportional to
the relative quantitative UV intensity of each peak. The DeltaVue software quantitatively displays one protein map in shades of red and the other
map in shades of green. The difference between the two maps is obtained by point-by-point subtraction or by area difference and displayed as
a third map in the middle. The color (red or green) at a particular location in the difference map indicates which protein is more abundant, and
the color brightness indicates the quantitative difference. C, MALDI-TOF mass spectrum of ATP synthase a-subunit after trypsin digestion. MS-
Digest search using the peptide mass fingerprint data indicated that 10 peptides were matched with peptides from ATP synthase a-subunit,
giving sequence coverage of 28% (126/450 aa) of the protein.
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by the fourth round of selection. Thus, by Matrigel inva-
sive subpopulation selection, we were able to establish
the highly invasive and metastatic breast cancer cell line
MCF-7-H.
2-D liquid chromatography and MALDI-TOF MS analysis
Image analysis of the 2-D map revealed 72 protein peaks
with significantly differential expression between MCF-
7-H and MCF-7 cells, and 9 of these protein peaks were
further identified by tryptic digestion, peptide mass fin-
gerprinting and MS. Five proteins were down-regulated
and four proteins up-regulated in MCF-7-H cells,
including ATP synthase a-subunit. The display map of
differentially expressed proteins between the MCF-7-H
and MCF-7 cell lines and the MALDI-TOF/MS tryptic
peptide mass map of ATP synthase a-subunit are
shown in Figure 1B and 1C, respectively. MS-Digest
search using the peptide mass fingerprint data indicated
that 10 peptides were matched with peptides from ATP
synthase a-subunit, giving sequence coverage of 28%
(126/450 aa) of the protein. The amino acid sequence of
this protein can be accessed in the National Center for
Biotechnology Information (NCBI) protein database
under NCBI Accession # 4757810.
IHC and TMA analysis of ATP synthase a-subunit
IHC staining was performed on 214 cases in total. In all
33 normal breast epithelia, a weak or missing ATP
synthase a-subunit signal was detected at the cell mem-
brane and in the cytoplasm. The overall percentage of
atypical hyperplasia breast tissues staining positive for
ATP synthase a-subunit was 23.1% (3/13), while that in
breast cancer tissues was 94.6% (159/168) (Table 1).
Detection of the ATP synthase a-subunit was strong in
98 breast cancer patients (58.3%), moderate in 61
patients (36.3%) and negative in 9 patients (5.3%) (Table
2). The staining pattern was predominantly at the cellu-
lar membrane and cytoplasm (Figure 2E and 2F). The
cytoplasmic immunoreactivity was granular and
appeared in epithelial cells. Figure 2 shows an example
of the tissue array analysis for ATP synthase a-subunit
in breast cancer samples, atypical breast hyperplasia and
normal breast tissue. Expression of the ATP synthase a-
subunit in breast cancer (Figure 2C and 2D) was
significantly higher than in breast atypical hyperplasia
and normal breast tissues (Figure 2G, H, I, J and 2K).
The analysis showed that the higher ATP synthase a-
subunit expression was significantly associated with
tumor size, histological grade and stage (P < 0.05). No
statistically significant differences were found among
cases with different ages or lymph node invasion (P >
0.05) (Table 2). Analysis of gene expression data sets
from a cancer gene microarray meta-analysis public
database [27]http://www.oncomine.org revealed that
ATP synthase a-subunit mRNA expression is markedly
higher in carcinoma cell lines than in normal tissues
and cell lines (Additional file 1).
Analysis of ATP synthase a-subunit surface expression on
breast cancer cells by immunofluorescence microscopy
and flow cytometry
Immunofluorescence microscopy analysis using a speci-
fic antibody confirmed the surface localization of the
ATP synthase a-subunit on non-permeabilized MDA-
MB-231 cells (Figure 3A). Control experiments were
performed with isotype mouse IgG (Figure 3C, F) and
permeabilized cells in the presence of the anti-a-subunit
ATP synthase antibody (Figure 3B, E). While the per-
meabilized normal breast cell line MCF-10F (Figure 3E)
also reacted with the anti-ATP synthase a-subunit anti-
body, no specific reactivity was observed with non-per-
meabilized MCF-10F cells (Figure 3D). Surface
expression of ATP synthase on MDA-MB-231 and
MCF-10F cells were further assessed by flow cytometry.
The results showed a significantly higher proportion of
MDA-MB-231 cells (54.1 ± 12.4%) with ecto-expression
of the ATP synthase a-subunit compared with the IgG
isotype control group (2.4 ± 1.7%) (P < 0.01, Figure 4A,
B). No ecto-expression of the ATP synthase a-subunit
was detected in MCF-10F cells (4.5 ± 3.4%) when com-
pared with its control group (5.4 ± 2.5%) (P > 0.05, Fig-
ure 4A, B). We also detected the ecto-expression of
ATP synthase a-subunit in other three breast cell lines,
and the ecto-expression is from 5.83% to 52.72% in
these cell lines (Figure 4C)
Anti-proliferative effect of anti-ATP synthase a-subunit
antibody on breast cancer cells
To gain insight into the function of ATP synthase in
breast cancer and test whether ATP synthase represents
a potential therapeutic target, we used MAb9E10, an
anti-ATP synthase a-subunit mAb produced as pre-
viously described [26]. After blockade of surface ATPase
with this mAb on human breast adenocarcinoma MDA-
MB-231 cells, an ATP determination kit and CellTiter96
AQueous Assay (MTS) assay were used to detect the
effect of the antibody on extracellular ATP modification
and cell proliferation. Results showed that MAb9E10
Table 1 ATP synthase expression in normal, atypical
breast hyperplasia and breast cancer tissues
N ATP synthase expression P value
Negative Positive
Normal 33 26 7 (21.2%) < 0.001
Hyperplasia 13 10 3 (23.1%)
breast cancer 168 9 159 (94.6%)
P value of chi-square analysis.
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inhibited the MDA-MB-231 cell proliferation in a con-
centration-dependent manner. The growth of MDA-
MB-231 cells treated with MAb9E10 was significantly
suppressed compared with that of cells treated with IgG
control. The proliferation of cells (OD450 = 0.87 ± 0.65)
treated with MAb9E10 in the high dose group (100 μg/
ml) was significantly lower than that of the mIgG con-
trol group (OD450 = 1.98 ± 1.13) (Figure 5A). There
was no inhibition of proliferation when MCF-10F cells
were treated with high dose (100 μg/ml) MAb9E10
(OD450 = 2.19 ± 0.65), which was nearly equal to that
of the control group (OD450 = 2.47 ± 1.23) (Figure 5A).
Inhibition of MDA-MB-231 migration and invasion by
anti-ATP synthase a-subunit antibody
To investigate the effect of ATP synthase expression on
cell motility and whether ATP synthase is involved in
the progression and metastasis of breast cancer, the
MDA-MB-231 and MCF-10F metastatic breast cancer
cell lines were then tested for their directional motility
on fibronectin and for their invasion ablity in a chemo-
haptotactic invasion assay. MDA-MB-231 cells treated
with MAb9E10 (100 μg/ml) showed lower migration
ability (66.2% migration inhibition) compared with IgG
control treatment (P < 0.01; Figure 5B). There was no
significant inhibition of migration (7.8%) when MCF-
10F cells were treated with MAb9E10 at the same dose
(P > 0.05; Figure 5B). In trans well assays, MDA-MB-
231 cells treated with MAb9E10 (100 μg/ml) also
showed a lower invasion ability (61.3% invasion inhibi-
tion) compared with IgG control treatment (P < 0.01;
Figure 5C). There was also no significant inhibition of
invasiveness of MCF-10F cells treated with MAb9E10 at
the same dose (3.4%) vs. the mIgG control group (P >
0.05; Figure 5C).
Anti-ATP synthase a-subunit antibody regulated
apoptosis pathway of MDA-MB-231 cells
In order to identify apoptosis and/or programmed cell
death molecules implicated into the treatment with anti-
ATP synthase a-subunit antibody, we used the
SABioscience Human Apoptosis PCR Array PAHS-3012.
We analyzed the expression of 370 key genes involved
in apoptosis, or programmed cell death with this PCR
Array (Figure 6A, B). This array includes the TNF
ligands and their receptors; members of the bcl-2 family,
BIRC (baculoviral IAP repeat) domain proteins, CARD
domain (caspase recruitment domain) proteins, death
domain proteins, TRAF (TNF receptor-associated factor)
domain proteins and caspases. Using this real-time PCR,
we can easily and reliably analyze the expression of a
focused panel of genes related to apoptosis with this
array. Comparison of PCR results between Test group
and control group showed that 23 genes were signifi-
cantly up-regulated and 18 genes were significantly
down-regulated both in test group1 and 2 (fold changes
Table 3 and Table 4). The raw data of PCR array was
attached in additional file 2. Results showed that treated
Table 2 Clinic pathological data and ATP synthase a-subunit expression in 168 breast cancers
a-ATP synthase expression Total P value
Negative Moderate Strong
Age
< 50 5 (7.0%) 30 (42.3%) 36 (50.7%) 71(100%) Not significant
≥ 50 4 (4.1%) 31 (32.0%) 62 (63.9%) 97 (100%)
Size
< 2 cm 2 (13.3%) 10 (66.7%) 3 (20.0%) 15 (100%) P < 0.05
≥ 2 cm 2 (3.6%) 24 (42.8%) 30 (53.6%) 56 (100%)
Histological grade
Well differentiated 3 (12.5%) 11 (45.8%) 10 (41.7%) 24 (100%) P < 0.05
Moderately differentiated 6 (5.3%) 43 (37.7%) 65 (57.0%) 114 (100%)
Poorly differentiated 0 (0.0%) 3 (15.0%) 17 (85.0%) 20 (100%)
TNM Stage
I 2 (22.2%) 4 (44.5%) 3 (33.3%) 9 (100%) P < 0.05
II 2 (4.6%) 24 (54.5%) 18 (40.9%) 44 (100%)
III 0 (0.0%) 3 (23.1%) 10 (76.9%) 13 (100%)
Lymph node invasion
Positive 3 (5.9%) 18 (35.3%) 30 (58.8%) 51 (100%) Not significant
Negative 2 (4.8%) 11 (26.2%) 29 (69.0%) 42 (100%)
P value of chi-square analysis.
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with Anti-ATP synthase a-subunit antibody, a lot of
apoptosis induced genes were up-regulated: FOXO1
(30.64), CASP9 (17.37) and CASP7 (4.43). A lot of anti-
apoptotic genes were down-regulated at the same time:
CARD9 (-34.63), CCL2 (-16.47) and BIRC3 (-9.66).
These data could partially explain the function of Anti-
ATP synthase a-subunit antibody.
Discussion
In this study we combined several advanced techniques,
such as proteomic analysis using the Proteome Lab PF
2D fractionation system, MALDI-TOF/MS and tissue
microarray, with functional analysis to identify novel
biomarkers for improved prediction of progression,
metastasis and response to therapy for breast cancer.
The work was also performed in an attempt to better
understand molecular mechanisms involved in breast
cancer carcinogenesis and metastasis. Our studies
revealed one highly over-expressed protein, the a-
subunit of ATP synthase, in breast cancer. This observa-
tion was validated, refined and extended through a ser-
ies of IHC on tissue microarray, immunofluorescence
and functional analyses. The over-expression of ATP
synthase a-subunit was detected by IHC in several dif-
ferent human tumor samples, including breast cancer,
hepatocellular carcinoma, colon cancer and prostate
cancer (data not shown). Since ATP synthase a-subunit
was highly over-expressed in 94.6% of breast cancer
samples tested while being undetectable in normal
breast tissues, this study was focused on the expression,
functional implication and potential involvement of
ATP synthase in the progression and metastasis of
breast cancer. Levels of ATP synthase a-subunit expres-
sion were strongly correlated with large tumor size,
poor tumor differentiation and advanced stages of
tumor. High expression of ATP synthase in breast can-
cer compared to normal breast tissue and hyperplasia
indicates that it can serve as a biomarker in screening,
Figure 2 IHC analysis of ATP synthase a-subunit expression in breast cancer tissue, atypical breast hyperplasia and normal breast
tissue. The breast cancer tissue microarrays were probed with the anti-ATP synthase a-subunit mAb (brown), and hematoxylin was used for
counterstaining (blue). A, A representative arrangement of “spots” on the breast cancer tissue microarray slide. B, Low-power magnification
shows strong and moderate immunoreactivity samples on the microarray slide (40×). C and D, Examples of a strong and a moderate
immunostaining, respectively, of ATP synthase a-subunit in epithelial cells of breast infiltrating duct carcinoma samples at increased
magnification (200×). E and F, A high-power view suggests immunoreactivity of the ATP synthase a-subunit antibody in the cellular membrane
and granular cytoplasmic distribution (400×). G, Absent staining in normal breast tissue. Original magnification (200×). H, I, J and K, Atypical
breast hyperplasia exhibiting a less intense (H and I) or absent immunostaining (J and K) at low-power (H and J, 200×) and high-power (I and K,
400×) magnifications.
Pan et al. Journal of Translational Medicine 2011, 9:211
http://www.translational-medicine.com/content/9/1/211
Page 8 of 15
diagnosis and prediction of breast cancer progression.
ATP synthase expression may also be useful when used
in combination with more traditional pathologic indica-
tors such as tumor size, TNM stage and tumor grade to
ascertain the prognosis of breast cancer patients.
Prior studies using DNA arrays relied on the expres-
sion of gene transcript in cancers, with little focus on
the detection of the protein [28]. With the recent devel-
opment of similar technologies at the DNA and protein
levels and several studies demonstrating the clinical
potential of the proteomic approach, there is no reason
to limit profiling to RNA. Proteomic analysis has the
potential to complement and further enlarge the wealth
of information generated by genomics for several rea-
sons. Levels of mRNA levels do not necessarily correlate
with corresponding protein abundance, as additional
complexity is conferred by protein post-translational
modifications, including phosphorylation, acetylation
and glycosylation, or protein cleavage. These modifica-
tions are not detectable at the mRNA level but play sig-
nificant roles in protein stability, localization,
interactions and functions. Finally, proteins represent
more accessible and relevant therapeutic targets than
nucleic acids. Thus, we surveyed primary breast cancers
for expression of ATP synthase by immunostaining with
the mouse anti-a-subunit ATP synthase antibody and
found a high frequency of immunoreactivity.
During energy generation in the mitochondria, the
ATP synthase is driven by a gradient of protons across a
membrane, produced by the organelle’s oxygen-burning
metabolism [13]. However, in a low oxygen or acidosis
microenvironment, where mitochondria ATP synthase
levels are very low, the cell surface ATP synthase of
tumor cells may manufacture the ATP using the gradi-
ent from the inside of cells compared to the outside,
which could result from the lack of oxygen [29-31].
When mitochondria are in low oxygen conditions or
matrix pH decreases, the proton gradient favorable for
ATP synthesis declines [32]. Therefore, it may be more
feasible for the cell in such an environment to produce
ATP on its surface. For example, ATP synthase shows
greater activity under conditions of acidosis, a hallmark
of the tumor microenvironment [33]. Cell-surface-gener-
ated ATP may be transported into the cell to provide a
Figure 3 Immunofluorescence localization of the ATP synthase a-subunit on the surface of breast cancer cells by confocal microscopy.
Cells were stained with an a-ATP synthase antibody, followed by secondary antibody, as detailed in Materials and Methods. A and D, Non-
permeabilized MDA-MB-231 and MCF-10F immunostained with a murine mAb specific for the ATP synthase a-subunit(600×). B and E, Image
obtained from MDA-MB-231 and MCF-10F cells permeabilized with ethanol (100%). C and F, Control experiments for antibody specificity using
isotypic purified mouse IgG in cells(600×).
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source of energy in the tumor microenvironment where
intracellular levels are very low. It is hypothesized that
certain lethal tumor phenotypes, such as invasion and
metastasis, arise not only from genetic alterations within
the tumor but from tumor microenvironmental stimuli,
such as acidosis. Endothelial and tumor cells could also
have a plentiful supply of ADP for conversion to ATP
to provide cancer cells with an extra energy source for
survival since red blood cells release high levels of ADP
in low-oxygen conditions.
Cellular invasiveness is an enhanced or aberrant cell
movement and a major characteristic of poorly differen-
tiated cancers [34]. In metastatic cancers, cells usually
acquire the ability to invade surrounding tissues and
then metastasize to secondary lesions. Therefore, the
aberrant motile feature of cancer cells is responsible for
Figure 4 Detection of ATP synthase a-subunit on the surface of breast cancer cells by flow cytometry. MCF-7, MCF-7H, MDA-MB-453,
MDA-MB-231 and MCF-10F cells were analyzed by flow cytometry as described in Materials and Methods. Histogram plots are shown of cells,
determined to be intact by propidium iodide exclusion, which were labeled with 7H10-BD4 mAb for the a-subunit of ATP synthase or control
mouse IgG. Significantly higher ecto-expression of ATP synthase a-subunit was found in MCF-7H, MDA-MB-453, MDA-MB-231 cells compared
with control IgG staining. No significant ecto-expression of ATP synthase a-subunit in MCF-7 and MCF-10F cells was observed compared with
the control.
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Figure 5 Inhibition of breast cancer cell proliferation, migration and invasion by a functional anti-ATP synthase a- subunit antibody. A
, MDA-MB-231 and MCF-10F were plated at a density of 5,000 cells/well in serum-free media for overnight fasting. The a-subunit of ATP
synthase was added at concentrations of 10 μg/ml (low dose), 50 μg/ml (medium dose) or 100 μg/ml (high dose). CCK-8 solution was added
after 24 h, and the absorbance used to calculate percent proliferation was measured on a Thermo max plate reader at a wavelength of 490 nm.
Growth of MDA-MB-231 cells treated with high dose MAb9E10 was significantly suppressed compared with IgG control treatment. MCF-10F cell
proliferation was not inhibited by MAb9E10 treatment. B, Migration of MDA-MB-231 and MCF-10F cells were measured using wound-healing
assays. MDA-MB-231 cells treated with MAb9E10 100 μg/ml showed lower migration ability comparing with mIgG control; ** P < 0.01. No
significant inhibition of migration was observed when MCF-10F cells were treated with MAb9E10. C, Invasion of MDA-MB-231 cells was
measured using transwell inserts coated with fibronectin (10 μg/ml). After treatment with anti-ATP synthase a-subunit antibody or control mIgG,
cells that migrated through the filters onto the lower surface were fixed, stained and photographed (200×). In each individual experiment, the
invaded cells were counted from at least three randomly selected fields. Results were averaged from at least three individual experiments. MDA-
MB-231 cells treated with MAb9E10 100 μg/ml also showed lower invasion ability comparing with mIgG control (Figure 5C). Almost no inhibition
of invasion when MCF-10F cells treated with MAb9E10. The bar graph displays means ± S.D; ** P < 0.01.
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Figure 6 Anti-ATP synthase a-subunit antibody regulated apoptosis pathway of MDA-MB-231 cells. Gene’s expression of MDA-MB-
231cells was measured using SABioscience Human Apoptosis PCR Array PAHS-3012. Three samples were analyzed: Control group, MDA-MB-231
cells treated with IgG for 24 hours; Test group 1, MDA-MB-231 cells treated with MAb9E10 100 mg/ml for 24 hours; Test group 2, MDA-MB-231
cells treated with MAb9E10 100 mg/ml for 48 hours. Calculate the ΔCt for each pathway-focused gene in each treatment group. ΔCt (group) =
average Ct - average of HK genes’ Ct for group array. Calculate the ΔΔCt for each gene across two PCR Arrays (or groups). ΔΔCt = ΔCt (Test group)
- ΔCt (Control group). Calculate the fold-change for each gene from Test group to control group as 2-ΔΔCt. A, Gene expression fold difference
between Test group 1 and Control group. B, Gene expression fold difference between Test group 2 and Control group.
Table 3 Up regulated genes of MDA-MB-231 cells treated with MAb9E10 antibody 24 and 48 hours (Fold change)
Symbol UniGene Description 24 h group 48 h group
1 FOXO1 Hs.370666 Forkhead box O1 17.95 30.64
2 CASP9 Hs.329502 Caspase 9, apoptosis-related cysteine peptidase 2.67 17.37
3 NDUFS3 Hs.502528 NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30 kDa (NADH-coenzyme Q reductase) 7.48 10.73
4 HSPA1B Hs.274402 Heat shock 70 kDa protein 1B 7.68 9.62
5 COL4A3 Hs.570065 Collagen, type IV, alpha 3 (Goodpasture antigen) 2.23 8.86
6 NFKB1 Hs.654408 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 6.71 6.3
7 F2R Hs.482562 Coagulation factor II (thrombin) receptor 6.59 5.38
8 CRYAB Hs.408767 Crystallin, alpha B 6.62 4.97
9 SOCS2 Hs.485572 Suppressor of cytokine signaling 2 4.09 4.89
10 NOD2 Hs.592072 Nucleotide-binding oligomerization domain containing 2 6.46 4.88
11 PIK3R2 Hs.371344 Phosphoinositide-3-kinase, regulatory subunit 2 (beta) 1.72 4.75
12 PRKCE Hs.580351 Protein kinase C, epsilon 2.83 4.66
13 CASP7 Hs.9216 Caspase 7, apoptosis-related cysteine peptidase 4.85 4.43
14 TBX3 Hs.714737 T-box 3 3.6 4.24
15 BIRC8 Hs.348263 Baculoviral IAP repeat containing 8 2.88 4.08
16 PIM2 Hs.496096 Pim-2 oncogene 4.23 3.79
17 HSPB1 Hs.520973 Heat shock 27 kDa protein 1 1.75 3.76
18 IL31RA Hs.55378 Interleukin 31 receptor A 3.46 3.46
19 MADD Hs.82548 MAP-kinase activating death domain 2.06 3.43
20 PEA15 Hs.517216 Phosphoprotein enriched in astrocytes 15 7.8 3.38
21 BNIP1 Hs.145726 BCL2/adenovirus E1B 19 kDa interacting protein 1 5.48 3.28
22 CASP14 Hs.466057 Caspase 14, apoptosis-related cysteine peptidase 7.09 3.09
23 MAL Hs.80395 Mal, T-cell differentiation protein 2.42 3.04
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the initial phase of cancer metastasis, and cell motility
or invasiveness is one of the multiple steps that can be
inhibited by a cancer metastasis suppressor. ATP
synthase may also play critical roles in tumor cell
metastases. It was previously identified as the binding
target of angiostatin, a potent antagonist of angiogen-
esis and the growth of tumor cell metastases
[16,35,36]. F1-F0-ATP synthase constitutes the major
(endothelial cells) EC-binding site for angiostatin,
which is active in ATP synthesis and inhibits the
endothelial cells proliferation by blocking conforma-
tional changes of the enzyme complex required for
ATP synthesis or hydrolysis. ATP synthase activities of
the enzyme are inhibited by angiostatin as well as by
antibodies directed against the a- and b-subunits of
ATP synthase in cell-based and biochemical assays.
These experimental results suggest that the inhibitors
of ATP synthase activity, such as antibodies against
ATP synthase, function as antagonists of angiogenesis.
Recent studies also suggested that the polyclonal or
monoclonal antibodies against the b-catalytic subunit
of F1F0 ATPase could efficiently inhibit the activities
of ecto-F1F0 ATPase. Wang et al. [37] demonstrated
inhibition of tumor growth in a hepatoma xenograft
mouse model using a monoclonal antibody
(mAb6F2C4) against the catalytic b subunit of ATP
synthase. In accordance with findings of Chi et al [38].
and Zhang et al [26] treating MDA-MB-231 cells and
HUVECs with other monoclonal antibodies against the
b subunit of ATP synthase the authors show that
mAb6F2C4 inhibits extracellular ATP synthesis to a
greater degree at low pH (6.7) than at normal pH (7.4).
In order to identify apoptosis and/or programmed cell
death molecules implicated into the treatment with anti-
ATP synthase a-subunit antibody, we analyzed the
expression of 370 key genes involved in apoptosis, or
programmed cell death with this PCR Array. PCR
Arrays are the most reliable tools for analyzing the
expression of a focused panel of genes. High-quality pri-
mer design and master mix formulation enable the PCR
Array to amplify 384 different gene-specific products
simultaneously under uniform cycling conditions. A lot
of new genes were identified and these genes may relate
with the function of Anti-ATP synthase a-subunit
antibody.
In the present study, two breast tissue cell lines,
MDA-MB-231, the highly invasive breast cancer cell line
with a relatively higher level of cell surface ATP
synthase a-subunit, and MCF10F, an immortalized
(non-tumor derived) human breast epithelial cell line
with no detectable level of cell surface ATP synthase,
were selected to study the role of ATP synthase in can-
cer cell proliferation and migration. The anti-ATP
synthase a-subunit antibody exerted a significant inhibi-
tory effect on the proliferation and migration of the
breast cancer cells. To our knowledge, our study showed
for the first time that antibody mediated blockade of the
ATP synthase a-subunit antibody can inhibit breast can-
cer cells and attenuate the directional cell migration of
cancer cells in vitro. Although ATP synthase may also
play critical roles in tumor cell metastases as the bind-
ing target of angiostatin in endothelial cells, a potent
antagonist of angiogenesis and the growth of tumor cell
metastases, our results showed that an anti-ATP
Table 4 Down regulated genes of MDA-MB-231 cells treated with MAb9E10 antibody 24 and 48 hours (Fold change)
Symbol UniGene Description 24 h group 48 h group
1 CARD9 Hs.694071 Caspase recruitment domain family, member 9 -3.18 -34.63
2 CCL2 Hs.303649 Chemokine (C-C motif) ligand 2 -5.91 -16.47
3 CUL3 Hs.372286 Cullin 3 -20.23 -10.06
4 BIRC3 Hs.127799 Baculoviral IAP repeat containing 3 -3.96 -9.66
5 IL18 Hs.83077 Interleukin 18 (interferon-gamma-inducing factor) -2.05 -8.89
6 TP63 Hs.137569 Tumor protein p63 -3.43 -8.6
7 SPP1 Hs.313 Secreted phosphoprotein 1 -2.88 -7.61
8 TNFRSF21 Hs.443577 Tumor necrosis factor receptor superfamily, member 21 -3 -6.72
9 F2 Hs.655207 Coagulation factor II (thrombin) -35.19 -5.9
10 AIFM3 Hs.163543 Apoptosis-inducing factor, mitochondrion-associated, 3 -1.56 -5.79
11 CARD8 Hs.446146 Caspase recruitment domain family, member 8 -3.07 -5.52
12 PMAIP1 Hs.96 Phorbol-12-myristate-13-acetate-induced protein 1 -4.52 -4.7
13 CD27 Hs.355307 CD27 molecule -2.63 -4.34
14 HMGB1 Hs.593339 High mobility group box 1 -1.74 -4
15 INHA Hs.407506 Inhibin, alpha -5.02 -3.75
16 TP53I3 Hs.50649 Tumor protein p53 inducible protein 3 -1.89 -3.74
17 BRCA1 Hs.194143 Breast cancer 1, early onset -1.99 -3.49
18 MYBL2 Hs.179718 V-myb myeloblastosis viral oncogene homolog (avian)-like 2 -2.42 -3.32
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synthase a-subunit antibody directly inhibited the tumor
cell migration. Thus, decreased cell motility and migra-
tion likely play a major role in ATP synthase mediated
cancer metastasis. The suppression of cell migration by
the anti-ATP synthase a-subunit antibody was not lim-
ited to a specific ECM interaction.
Conclusions
In summary, our results demonstrated that over-
expression of ATP synthase a-subunit may be involved
in the progression and metastasis of breast cancer, and
it may represent a potential biomarker for diagnosis
and a promising therapeutic target for anti-tumor and
anti-metastasis therapy. The development of antibodies
to ATP synthase in place of angiostatin mimetics may
be advantageous due to increased specificity and affi-
nity. An antibody against ATP synthase may ultimately
prove useful, either alone or in combination with other
treatments, to improve the effectiveness of breast can-
cer therapy.
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